EyePoint Pharmaceuticals (STU:PV3B) Gross Margin %

: 92.89% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. EyePoint Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was €11.95 Mil. EyePoint Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €12.86 Mil. Therefore, EyePoint Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 92.89%.

The historical rank and industry rank for EyePoint Pharmaceuticals's Gross Margin % or its related term are showing as below:

STU:PV3B' s Gross Margin % Range Over the Past 10 Years
Min: 77.86 Med: 83.09 Max: 89.93
Current: 89.93

During the past 13 years, the highest Gross Margin % of EyePoint Pharmaceuticals was 89.93%. The lowest was 77.86%. And the median was 83.09%.

STU:PV3B's Gross Margin % is ranked better than
85.58% of 735 companies
in the Biotechnology industry
Industry Median: 60.01 vs STU:PV3B: 89.93

EyePoint Pharmaceuticals had a gross margin of 92.89% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for EyePoint Pharmaceuticals was 0.00% per year.

EyePoint Pharmaceuticals Gross Margin % Historical Data

The historical data trend for EyePoint Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

86.80

83.09

77.86

79.89

89.93

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															67.63	91.67	80.32	92.09	92.89

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Gross Margin % falls into.

EyePoint Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

EyePoint Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	38	/	42.199
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(42.199 - 4.248)	/	42.199
	=	89.93 %

EyePoint Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	11.9	/	12.864
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(12.864 - 0.915)	/	12.864
	=	92.89 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

EyePoint Pharmaceuticals (STU:PV3B) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

EyePoint Pharmaceuticals had a gross margin of 92.89% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

EyePoint Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines